Atrium Therapeutics Secures $15M Milestone, Opens $1.35B R&D and $825M Commercial Potential
Atrium Therapeutics received a $15 million milestone payment from Bristol Myers Squibb after delivering its first licensed RNA-based cardiology development candidate, marking initial progress under their global cardiovascular collaboration. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities while Atrium remains eligible for up to $1.35 billion in R&D milestones, $825 million in commercial milestones and low-double-digit royalties.
1. Milestone Payment Achievement
Atrium Therapeutics earned a $15 million development milestone payment from Bristol Myers Squibb following the successful delivery of its first licensed RNA-based cardiology candidate. This achievement marks the initial progress under their global licensing agreement focused on cardiovascular RNA therapeutics.
2. Collaboration Terms and Financial Upside
Under the collaboration, Atrium is eligible to receive up to $1.35 billion in research and development milestones, $825 million in commercial milestones and low-double-digit royalties on net sales. Bristol Myers Squibb will assume full funding responsibility for all future clinical development, regulatory submissions and commercialization activities related to the partnership.
3. Pipeline and Platform Development
Atrium's RNA delivery platform combines targeted monoclonal antibody ligands with precision oligonucleotides to address genetically driven cardiac diseases. The company's pipeline includes two precision cardiology programs—ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy—alongside two undisclosed rare cardiomyopathy targets.